The study on radioligand therapy by 177Lu-EB- PSMA-617 shows promising clinical response [109,110], suggesting that PSMA could be a targetable antigen in immunotherapy against AdCC. Here, FOLH1 is linked to adrenocortical carcinoma, hereditary.